IJFANS INTERNATIONAL JOURNAL OF FOOD AND NUTRITIONAL SCIENCES
ISSN PRINT 2319 1775 Online 2320 7876
Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 12, 2022

Beta Amyloidal Inhibitors In Alzheimer Disease: A Review

Khansole Jayshri kondibarao[1]

1. Lecturer, Yeshwant college Nanded, MH

Corresponding author-

Khansole Jayshri kondibarao

Email- bokaremadhav@yahoo.com

Abstract: Alzheimer's disease (AD) likely results from a variety of circumstances, which makes understanding the molecular mechanisms behind the neuropathology of the illness challenging. Consequently, it is not unexpected that a variety of potential therapy modalities addressing various features of this condition are now being researched. They include methods to stop the accumulation of amyloid, stop neuronal deterioration, and raise levels of brain neurotransmitters. Here, we go through potential roles for endogenous inhibitors of amyloid aggregation in AD as well as a few of the approaches being considered right now to affect the quantities of amyloid in the brain, its aggregation, and its neurotoxicity. In the future, a viable strategy for the prevention and treatment of AD may consist of stimulating the body's natural system for peptide clearance and inhibiting amyloid aggregation. There is an urgent need for novel therapeutics for Alzheimer's disease (AD). Phase I, phase II, and phase III are the stages of the drug development process. On the federal government's database, trials are listed.

Keywords: Alzheimer’s Disease, β-amyloid, Inhibitor, Aβ aggregation, Beta Amyloid Peptide, Amyloid β Oligomer, Modulators etc.

ISSN PRINT 2319 1775 Online 2320 7876
 UGC CARE Listed (Group -I) Journal Volume 11, Iss 12, 2022

Introduction

Alzheimer's disease is an incurable, progressive brain disorder that steadily robs people of their memory and reasoning abilities and, eventually, their capacity to complete even the most basic tasks. When cognitive and behavioural abilities are lost to the point where they interfere with a person's day-to-day activities, this condition is known as dementia. The area of the brain responsible for memory formation, the hippocampus, initially appears to be damaged. The most common cause of dementia in those over 65 worldwide (50–70% of all dementia cases) is Alzheimer disease (AD), a neurodegenerative illness with a progressive course [1]. Many brain processes, primarily at the cortical and hippocampal levels, including memory, thinking, direction, understanding, computation, learning ability, language, and judgement, are affected by this chronic and progressive disease [2]. Emotional self-control and social behaviour also deteriorate along with changes that cause cognitive deficiency. AD is viewed as a significant public health issue due to the disease's high prevalence and significant socioeconomic implications to society. Research into it is currently prioritised since statistics suggest that it may be the "pandemic of the 21st century." The treatments that are currently available for AD are all symptomatic, meaning that they diminish the disease's symptoms by working on various levels of the neuropathological process, despite the significant scientific and clinical advancements made in AD research over the past 30 years. None of them can effectively stop the rapid, fatal progression of the disease, even if they can all enhance patients' quality of life. Only 4 presently marketed medications have been authorised to treat AD as of this writing. They fall into two categories: N-methyl-Daspartate receptors and acetylcholinesterase inhibitors (AChEI) (NMDAR). The AChEI group of medications includes galantamine, rivastigmine, and donepezil [2-4]. AChEI medications work by increasing cholinergic transmission by inhibiting acetylcholinesterase in the synaptic cleft; this procedure may slightly improve cognitive function in AD patients. Memantine is an NMDAR antagonist; because glutamate levels are pathologically high in AD, it decreases excitotoxicity by inhibiting that ionotropic receptor. For patients with AD who are in the moderate phases of the disease, both medication groups are recommended [3,4]. However, it has been established that none of these licenced medications works as a cure; rather, they are only used as palliative measures, and their efficacy wanes with time.

According to the amyloid hypothesis of Alzheimer disease (AD), the build-up of the amyloid-(A) peptide causes neurodegeneration, synaptic malfunction, and eventually symptoms [5]. Most prospective disease-modifying therapies created in recent years target A, including A

ISSN PRINT 2319 1775 Online 2320 7876
 UGC CARE Listed (Group -I) Journal Volume 11, Iss 12, 2022

aggregation inhibitors and inhibitors of the synthetic enzyme's secretase and -secretase. The most sophisticated anti-A strategy, however, is immunotherapy, which combines passive immunisation with the introduction of exogenous antibodies with active vaccination to drive the immune system to manufacture its own antibodies. The benefit of active immunotherapy is the low-cost, long-lasting antibody generation that results from short-term medication delivery. Contrarily, immune response may be patchy or non-existent, especially in older people, and unfavourable effects, if immunologically based, may also be persistent. An unsuccessful experiment of AN1792 (full-length A-42 with QS-21 as adjuvant), which was stopped after T-cell mediated meningoencephalitis occurred in 6% of treated participants, tainted the initial experience with active vaccinations [6]. In order to circumvent T-cell epitopes at the C-terminus, second generation vaccines like ACC-001 [7-9] and CAD106 [10,11] aim to produce anti-A antibodies that are limited to the N-terminus. Only CAD106 has been chosen for the Alzheimer Prevention Initiative (API) APOE-4 homozygote research and has advanced to Phase 3 [12-14]. Passive immunisation, as opposed to active vaccination, provides the benefits of ensuring constant antibody titters and enabling control of adverse outcomes by ceasing therapy. Monoclonal antibodies' (mAbs) main limitations are their need for recurrent injections and associated production costs [15]. Many mAbs that have been developed to bind and clear A have moved to human trials over the past 15 years. Although there have been many failures and ambiguous outcomes in the testing of mAbs, the knowledge collected from these trials has given valuable insights that have made it possible to build better treatments.

β Amyloid Peptide [16-23]

One of the key components of the neuropathology of Alzheimer's disease is the amyloid peptide (A) (AD).

A is a peptide of 39–43 amino acid residues that is created by proteolytic cleavage of the amyloid precursor protein (APP), a big precursor that is encoded by a gene on human chromosome 21.

- APP remains an essential film glycoprotein, through a quick cytoplasmatic C-terminal end and a great extracellular N-terminal area.
- Enzyme recognized by way of secretases remain accountable aimed at proteolysis of APP besides announcement of Aβ. Aβ remains unconfined subsequent cleavage of APP on locations 597 then 637-639 by β- then γ-secretases, correspondingly.

ISSN PRINT 2319 1775 Online 2320 7876
Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 12, 2022

- γ-secretases whitethorn slash APP on the C-terminal end of Aβ on 4 dissimilar locations, generous increase towards Aβ peptide.
- The meticulous location of C-terminal cleavage seems dangerous towards the growth of AD.
- Aβ procedures appearances non-covalent fibrillar aggregates, the situation combination then resultant amyloid statement cutting-edge the intelligence consume remained connected towards AD neurotoxicity.



ISSN PRINT 2319 1775 Online 2320 7876
Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 12, 2022

The neuropathology of AD is largely influenced by the -amyloid peptide (A) [24-26]. The amyloid precursor protein (APP), which is a big precursor and is encoded by a gene on human chromosome 21, is broken down into a peptide called A, which has 39–43 amino acid residues [27]. A wide extracellular N-terminal domain and a small cytoplasmic C-terminal tail distinguish the integral membrane glycoprotein known as APP [28]. Secretases are enzymes that cause the proteolysis of APP and release of A [29]. The extracellular domain of APP accounts for the first 28 amino acid residues of A, while the transmembrane area accounts for the following 11–15 residues [30]. After cleavage of APP by - and -secretases at sites 597 and 637 and 639, respectively, A is released [31]. Recent research has revealed that aspartic protease is -secretase [32,33]. A peptide with a length of 39–43 amino acids can be produced by four alternative sites of APP cleavage by -secretase at the C terminal end of A. As the production of the more amyloidogenic peptides (such A1-42 or A1-43) is highly correlated with the development of AD [34-36], the precise site of C-terminal cleavage appears to be important to the development of AD. The exact molecular makeup of -secretase is still unknown. Recent data, however, points to the possibility that presenilin's 1 and 2, working together with the protein Nicastro, may make up the -secretase complex that releases A [37]. The main protein discovered in the senile plaques that are present in the brains of AD patients is A [38,39]. Both in vitro and in vivo, A forms distinctive non-covalent fibrillar aggregates, and its aggregation and the following amyloid deposition in the brain have been linked to AD neurotoxicity [40,41]. Amyloid fibril formation in vitro can be affected at different stages by substances that either promote or prevent aggregation. These elements include interactions with different biomolecules, pH fluctuations, peptide concentration, and variations in its fundamental sequence [42,43]. The interaction of at least some of these factors is probably what contributes to the in vivo formation of amyloid plaques. To prevent amyloid aggregation and toxicity, it may be able to intervene therapeutically by understanding the physiological processes involved in an aggregation and the relationships that are crucial for amyloid stability.

Modulators of Amyloid Aggregations



It has been shown that amyloid plaques in AD brains are connected with a wide variety of biomolecules, such as proteins, proteoglycans, lipids, metals, and other tiny molecules. While it's probable that some of these molecules are connected to incidental amyloid deposition processes, in vitro and in vivo research has shown that several of them may control A aggregation. It should be noted that there is a delicate balance between the generation, aggregation, and clearance of A in the brain, thus even substances that have a very little impact on A aggregation in vitro may have a big impact on how those events are regulated in vivo. Several plasma proteins have been demonstrated to regulate A polymerization at physiological concentrations [44]. With IC50 values much below their plasma concentrations, albumin, 1-antitrypsin, IgG, and IgA are powerful inhibitors of A fibrillogenesis [45]. These proteins, though, are scarce in CSF fluid and may have little to no impact on the aggregation of A. Since albumin is the most prevalent protein in cerebral fluid, but because it is present at a concentration below its IC50 value, it may only partially impede A polymerization [46]. The serpin family of serine protease inhibitors includes the acute phase response protein, 1-antichymotrypsin, which is increased as a result of inflammatory events. Only in cases of Alzheimer's disease has co-localization of 1-ant chymotrypsin been seen with amyloid plaques [47], pointing to a particular relationship with A. The presence of 1-antichymotrypsin at high doses promotes amyloid aggregation [48]. In contrast, 1-antichymotrypsin prevents the production of amyloid and breaks up previously formed aggregates at low concentrations [49,50].

In the latter instance, independent research has demonstrated that interactions between 1-antichymotrypsin and A sequences 11-28/29-42 are important in inhibiting fibrillogenesis [51]. Moreover, recent research has demonstrated that transgenic mice overexpressing 1-antichymotrypsin and expressing human APP generate amyloid plaques at a considerably higher rate and earlier age than mice expressing only human APP [52]. A second acute fase protein, 2-macroglobulin, binds with A, inhibits fibril formation [53], and reduces the neurotoxicity of the -amyloid peptide in cultured rat foetal cortical neurons [54]. Heparan sulphate [55], keratan sulphate [56], dermatan sulphate [57], and chondroitin sulphate [58] are among the different forms of glycosaminoglycan (GAG) chains that have been linked to amyloid plaques in AD. According to several studies [59-63], GAGs support and sustain the development of amyloid fibrils.

GAGs' effects on fibrillogenesis seem to be mediated by electrostatic interactions between A and the highly sulfated chains of GAGs [64]. The structural conversion of A to -sheet

ISSN PRINT 2319 1775 Online 2320 7876
 UGC CARE Listed (Group -I) Journal Volume 11, Iss 12, 2022

structures is the outcome of these interactions, which happen early in the process of fibril formation [65]. A decrease in fibril production in the presence of desulphated heparan sulphate in tests underlined the significance of sulfated groups in amyloid aggregation [66]. Hence, it is thought that comprehending the interactions between A and sulfated GAGs may result in efficient amyloid aggregation inhibitors [67]. In vitro A aggregation appears to be variably influenced by apolipoprotein E (ApoE) isoforms, which either promote or inhibit aggregate formation [68,69].

Purified ApoE2, ApoE3, and ApoE4 (used at the amounts at which they are found in cerebral fluid) have all been utilised to study metal-induced aggregation of A [70]. This study demonstrated that the presence of ApoE4 increased the amount of metal-induced A aggregation for both copper and zinc. ApoE2 and ApoE3, but not ApoE4, protect cortical neurons against neurotoxicity brought on by A, according to a recent study [71]. Apolipoprotein J (clustering), a multifunctional apolipoprotein produced by cells in the brain and other organs, is linked to aggregated A in Alzheimer's disease diffuse plaques and senile plaques (AD). The aggregation of A has been demonstrated to be partially blocked by Apo J [72]. Furthermore, A is more resistant to trypsin and chymotrypsin-induced proteolysis when complexed to Apo J [73].

Recent research has revealed that the high-density lipoprotein complex component apolipoprotein A-I (Apo A-I) interacts directly with the amyloid precursor protein (APP) to prevent A aggregation and toxicity [74]. One of the postulated pathways of neurodegeneration in Alzheimer's disease involves activation of the complement system. The binding of C1q to A is what causes this activation [75]. At physiological concentrations, it has been demonstrated that C1q promotes A aggregation, and the kinetics of this enhancement are compatible with a nucleating interaction [76]. The enzyme acetylcholinesterase, which also frequently co-localizes with amyloid deposits, is involved in the breakdown of the neurotransmitter acetylcholine [77,78]. Acetylcholinesterase stimulates the aggregation of A in vitro by creating a compound with the expanding fibrils [79]. A hydrophobic region near the enzyme's peripheral anionic binding site has recently been demonstrated to be the mechanism by which acetylcholinesterase interacts with A [80]. Also co-localizing with senile plaques are elements of the basement membrane, such as entactin and laminin. Laminin and, more recently, entactin have both been reported to prevent the formation of A fibrils induced by ApoE4 in vitro [81,82]. Amyloid fibril formation is accelerated by interactions between A and

phosphatidylinositol, most likely because A changes structurally from a random coil to a sheet structure [83].

In contrast, tiny A aggregates are stabilised by inositol stereoisomers (sugars involved in lipid production, signal transmission, and control of osmolarity), which prevents the development of fibrils. The toxicity of A to neurons in culture is dramatically reduced when A and inositol form a compound. Inositol stereoisomers, which are biological molecules that can pass across the blood-brain barrier, could be used as pharmacological treatments for AD. At neutral pH, gangliosides cause A to adopt a distinctive -helical/sheet conformation. The interaction of A with glycolipids, such as gangliosides of the GM1 type, suppresses the formation of amyloid fibrils, and further research by the same group shown that the sialic acid moiety of gangliosides is required for the induction of -helical structure

Trimethylamine-N-oxide, a physiological osmolyte, and glycerol induce the conversion of Aβ from random coil to β-sheet structure, leading to the formation of tetrameric Aβ globular aggregates and early-stages protofibrils that are later transformed into mature fibrils [86]. Amyloid deposits observed in AD patients are also linked to metals like Zn2+, Fe3+, and Cu2+. Although the specific origins of these ions are still unclear, evidence suggests that they are produced from metalloproteins in mildly acidic environments during inflammatory responses [87]. In vitro and in vivo studies have demonstrated that Zn2+, Ni2+, or Cu2+ elicit rapid amyloid aggregation [88,89].

His13 has been discovered in amino acid replacement studies as the metal ion ligand of A. The structural transition from random coil to -sheet and fibrillogenesis are inhibited when His13 is changed to Arg. Recent studies have shown that Cu2+ chelators, such as trientine, penicillamine and bathophenanthroline can be used to solubilize Aβ aggregates extracted in PBS buffer from AD brains. These studies suggest that the combined properties of metal chelators and agents capable of dissolving Aβ aggregates can be complementary in the treatment of Alzheimer's disease [90].

Amyloid β Oligomer [91,92]

Amyloid beta oligomer remains minor collections of the β amyloid protein.

- ✓ The uncovering of amyloid- oligomers (AOs) cutting-edge humanoid intelligence parenchyma then vasculature remained primary stated though the unique amyloid cascade theory remained existence presented then industrialized.

ISSN PRINT 2319 1775 Online 2320 7876
 UGC CARE Listed (Group -I) Journal Volume 11, Iss 12, 2022

- ✓ Peptides collective towards method AOs, approximately of which additional collective towards fibrils then approximately of which prompt the nerve cell injury foremost toward dementia.
- ✓ Convinced misfolded oligomer container persuade additional A β particle toward income the misfolded oligomeric procedure.

Targeting β- Amyloid Creation

- ➢ Monoclonal antibodies
- ➢ Hormones
- ➢ Aβ peptide inhibitors
- ➢ Immunotherapy
- ➢ Clearance of Aβ

Monoclonal Antibodies

Monoclonal antibodies remain complete through undistinguishable resistant cells that remain altogether replicas of an exclusive parent cell.

Immune compound comprising two monoclonal antibodies (6C6 then 10D5) elevated in contradiction of the N-terminal area of Aβ disaggregated.

A novel antibody 508F , stop the neurotoxic result of Aβ .

Examples: Solanezumab, Aducanumab, UB-311, BAN2401.



AZD3293

Hormones

Hormones similar Melatonin interrelate through Aβ1-40 and Aβ1-42, constraining fibrillogenesis.

ISSN PRINT 2319 1775 Online 2320 7876
Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 12, 2022

The indole derivative, 3-indol-propionic acid, which remains physically connected toward melatonin. Exhibitions neuroprotective achievement in contradiction of Aβ poisonousness.

Estrogen control APP dispensation reason augmented emission of non-amyloidogenic remains sAPPα, then reduction Aβ peptide creation.

Immunization through Aβ Peptide

Immunization through Aβ peptide mains towards a important decrease cutting-edge intelligence amyloid plaques.

Antibodies elevated in contradiction of the Aβ peptide remained peripherally managed.

Example: PQ912 remains glutaminyl peptide cyclotransferase inhibitor.

Inhibition of Aβ peptide formation

This remains grounded happening reserve of the γ- then β-secretase actions before improvement of α-secretase action.

β-secretase (BACE) inhibitors with the peptidase inhibitor.

Inhibitors of γ-secretase action comprise difluoroketone, Bromo acetamide byproducts

Examples: JNS-54861911, LY3202626, E2609, AZD3293, CNP520, MK-8931.

Posiphen remains a discerning inhibitor of APP manufacture



Posiphen



E2609



AZD3293



CNP520

ISSN PRINT 2319 1775 Online 2320 7876
 UGC CARE Listed (Group -I) Journal Volume 11, Iss 12, 2022



JNJ54861911



LY2886721



LY2811376



MK-8931

Clearance of Aβ

Alzheimer's disease strength contains of cumulative the dilapidation then permission of Aβ. Inhibition of Aβ fibrillogenesis through 4-indo-4-deoxydoxorubicine (IDOX) affluences permission of the Aβ peptide.

Natural β amyloid inhibitors

Supplement through natural products after plants, for example *Hypericum perforatum* then *Ginkgo biloba* leaf excerpt EGb761, remains general aimed at the postponement of Alzheimer's disease.

Saffron derivatives

Crocus sativus L., a acaulescent perennial herb of the Iridaceae family, Saffron takes remained rummage-sale by way of a medication cutting-edge traditional drug, predominantly cutting-edge traditional Indian widespread medication, anywhere the situation consumes remained rummage-sale aimed at the action of numerous types of psychological infections.

Curcumin Derivatives

The curcumin byproducts constrain the β amyloid. Curcumin then connected mixtures remain Congo Red, Chrysalises G.

ISSN PRINT 2319 1775 Online 2320 7876
Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 12, 2022

The mechanical rudiments shared towards curcumin-like amyloid ligands. These geographies remain revealed cutting-edge relative toward a graphic Aβ superficial towards exemplify in what way these dissimilar mechanisms whitethorn donate towards molecular gratitude.

β Amyloid inhibitors in clinical trials

Table: β Amyloid inhibitors cutting-edge medical trials

Sr. no	Agent	Mechanism of Class	Sponsor	Phase of Clinical trial
1	Aducanumab	Monoclonal antibody	Biogen	Phase I
2	ALZT-OP1a+ALZT-OP1b	Inhibits neuro -inflammatory response	ATZ herapies	Phase I
3	CNP520	BACE inhibitor	Alzheimer's association	Phase I
4	E2609	BACE inhibitor	Eisai, Biogen	Phase I
5	Posiphen	Selective inhibitor of APP production	QR Pharma, ADCS	Phase II
6	JNJ-54861911	BACE inhibitor	Janssen	Phase II
7	LY3303560	Monoclonal antibody	Eli Lilly and Company	Phase III

ISSN PRINT 2319 1775 Online 2320 7876
Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 12, 2022

8	KHK6640	Amyloid aggregation inhibitor	Kyowa Hakko Kinn Co.	Phase III
9	LuAF20513	Polyclonal antibody	H. Lundbeck A/S	Phase III
10	NPT088	IgGI Fe-GAIM fusion	ProCare Biosciences	Phase I
11	Sargramostim	Synthetic granulocyte colony stimulator	Denver, The Dana Foundation	Phase II
12	Resagiline	Monoclonal oxidase B inhibitor	The C level and Clinic	Phase II
13	IDI 201	Phosphatidylinositol 3-kinase	II Dong Pharmaceuticals Co.	Phase II
14	Bryostatin1	Protein kinase C modulator	Neurotrop Biosciences	Phase II
15	ATP	Inhibit amyloid misfolding and toxicity	Fundaci6 Clinic per la Recerca Biomedica, Spain	Phase II
16	Atomoxetine	Adrenergic uptake inhibitor	Emony University, NIA	Phase II
17	Valacytovir	Antiviral agent	Umea University	Phase II

ISSN PRINT 2319 1775 Online 2320 7876
Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 12, 2022

18	PQ912	Glutaminyl peptide cyclotransferase inhibitor	Probiodrug AG, Julius clinical VU University	Phase I
19	Nilvadipine	Calcium channel blocker	St. James's Hospital Ireland, Alzheimer's Europe, Archer Pharmaceuticals	Phase I
20	AZD3293	BACE inhibitor	AstraZeneca, Eli Lilly	Phase III
21	MK-8931	BACE inhibitor	Merck	Phase III
22	NGP 555	Gamma secretase modulator	Neurogenetic Pharmaceuticals	Phase III
23	Crenezumab	Monoclonal antibody	Roche / Genenetech	Phase II
24	BAN2401	Monoclonal antibody	Eisai	Phase II
25	Solanezumab	Monoclonal antibody	Washington university , Eli Lilly , Roche,	Phase I
26	AZDO530 (saracatinib)	Kinase inhibitor	Yale University, ATRI, AstraZeneca	Phase II
27	CT1812	Sigma 2 receptor modulator	Cognition Therapeutics	Phase II
28	Albumin+ immunoglobulin	Polyclonal antibody Removed amyloid	Grifols	Phase III 2012

ISSN PRINT 2319 1775 Online 2320 7876
 UGC CARE Listed (Group -I) Journal Volume 11, Iss 12, 2022

29	Gantenerumab	Monoclonal antibody	Roche	Phase III 2014
30	CAD106	Amyloid Vaccine, BACE inhibitor	Novartis, Amgen, NIA,	Phase III 2015
31	GV-971	Inhibit amyloid aggregation	Shanghai Green Valley Pharmaceuticals	Phase III 2014
32	Candesartan	Angiotensin receptor blocker	Emory University	Phase II 2016
33	Nilotinib	Tyrosine kinase inhibitor	Georgetown University	Phase II 2017
34	S-equol	Estrogen receptor B agonist	Ausio Pharmaceuticals, University of Kansas	Phase II 2017

Conclusion

Potential treatment targets are provided by the newly discovered features of AD pathogenesis. There is currently no cure or viable medication to halt AD or stop its progression. To create efficient treatments, a variety of strategies addressing various facets of the condition are being studied, as was previously mentioned. In the future, a viable strategy for the prevention and treatment of AD may consist of stimulating the body's natural system for peptide clearance and inhibiting amyloid aggregation. There is an urgent need for novel therapeutics for Alzheimer's disease (AD). Phase I, phase II, and phase III of the drug development process are successive steps. On the federal government's database, trials are listed.

References

1. Thies W., Bleiler L. Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimer's Dement. 2013; 9:208—45.

2. Chiang K., Koo EH. Emerging therapeutics for Alzheimer's disease. Annu Rev Pharmacol Toxicol. 2014; 54:381—405.

3. Francis PT., Nordberg A., Arnold SE. A preclinical view of cholinesterase inhibitors in neuroprotection: Do they provide more than symptomatic benefits in Alzheimer's disease. Trends Pharmacol Sci. 2005; 26:104—11.

4. Huang Y., Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012; 148:1204—22.

5. Selkoe DJ., Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016; 8:595-608.

6. Gilman S., Koller M, Black RS., Jenkins L,, Griffith SG,, Fox NC. Clinical effects of A beta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005; 64:1553-1562.

7. Arai H., Suzuki H., Yoshiyama T. Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer's disease: results from two phase 2 studies. Curr Alzheimer Res. 2015; 12:242-254.

8. Pasquier F., Sadowsky C., Holstein A., Leterme Gle P., Peng Y., Jackson N. Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease. J Alzheimer's Dis. 2016; 51:1131-1143.

9. van Dyck CH., Sadowsky C., Prince G., Leterme G., Booth K., Peng Y. Vanutide cridificar (ACC-001) and QS-21 adjuvant in individuals with early Alzheimer's disease: amyloid imaging positron emission tomography and safety results from a Phase 2 study. J Prev Alzheimer's Dis.

10. Farlow MR., Andreasen N., Riviere ME., Vostiar I., Vitaliti A., Sovago J. Long-term treatment with active A beta immunotherapy with CAD106 in mild Alzheimer's disease. Alzheimer's Res Ther. 2015; 7:23.

11. Wimbled B., Andreasen N., Minthon L., Floesser A., Imbert G., Dumortier T. Safety, tolerability, and antibody response of active A beta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo controlled, first-in-human study. Lancet Neurol. 2012; 11:597-604.

12. Montoliu-Gaya L., Villegas S. A beta-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment. Expert Rev Mol Med. 2016; 18: e13.

13. Sarazin M., Dorothee G., de Souza LC., Aucouturier P. Immunotherapy in Alzheimer's disease: do we have all the pieces of the puzzle? Biol Psychiatry. 2013; 74:329- 332.

14. Reiman EM., Langbaum JB., Fleisher AS., Caselli RJ., Chen K., Ayutyanont N. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimer's Dis. 2011; 26 Suppl 3:321-329.

15. Lemere CA. Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol Neurodegener. 2013; 8:36.

16. Azza A Ali. Alzheimer's Disease: Pathophysiology, Hypotheses and Treatment . Strategies. Acta Psychopathic. I Med Pub journal. 2016; 2:3.

17. Ann S. Morrison., PhD RN., CS and Constantine Lyketsos, MD MHS. The Pathophysiology of Alzheimer disease and direction in treatment. Adv Stud Nurs. October 2005.

18. SAN DIEGO. The heart of Alzheimer's care and cure. Alzheimer's association. 2017; 56:86.

19. Petra Novotny., Jennifer M. Kwon., Alison M. Goate. Alzheimer's Disease. Encyclopedia of life sciences. Nature publishing group. 2001; 66:7.

20. Dennis J. Selkoe. Alzheimer's disease result from the cerebral accumulation and cytotoxic of amyloid β protein. Journal of Alzheimer disease. 2001; 3: 75-80.

21. Erika N. Cline., Maira Assuncao Bicca., Kirsten L. Viola and William L. Llein. The amyloid beta oligomer hypothesis Beginning of the Third Decade. 2018.

22. Jeffrey Cummings., Garam Lee., Trvis Mortsdorf., Aaron Ritter., Kate Zhong. Alzheimer's disease drug development pipeline Alzheimer's & Dementia. Translational Research & Clinical Interventions. 2018; 6:876.

23. Abraham CR., McGraw WT., Slot F and Yamin R. Alpha 1-ntichymotrypsin inhibits A beta degradation in vitro and in vivo. Ann sci. 2000; 920: 254-248.

24. Selkoe DJ. Cell biology of the amyloid beta protein precursor and the mechanism of Alzheimer's disease. Annu Rev Cell Biol. 1994; 10: 373-403.

25. Yankner BA. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron. 1996; 16 (5): 921-932.

26. Verbeek MM., Ruiter DJ and de Waal RM. The role of amyloid in the pathogenesis of Alzheimer's disease. Biol Chem. 1997; 378 (9): 937-950.

ISSN PRINT 2319 1775 Online 2320 7876
 UGC CARE Listed (Group -I) Journal Volume 11, Iss 12, 2022

27. Glenner GG and Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984; 120 (3): 885-890.

28. Kang J., Lemaire HG., Unterbeck A., Salbaum JM., Masters CL., Grzeschik KH., Multhaup G., Beyreuther K and Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell surface receptor. Nature. 1987; 325: 733- 736.